Verified factor-similar pair

ISMD vs PRFZ

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
88
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • PRFZ has the higher backtested relative Sharpe (0.963 vs 0.918).
  • PRFZ has the lower published fee (0.34% vs 0.59%).
  • ISMD is cheaper on dividend valuation (116 vs 153, where 100 is each fund's historical median).
  • PRFZ has the stronger regression fit (adjusted R-squared 0.974 vs 0.962).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

ISMD

Inspire Small/Mid Cap ETF
SMB
Adj. R2
0.962
Rel. Sharpe
0.918
Mkt beta
0.98
AUM
US$275M
MER
0.59%
Valuation
116

PRFZ

Invesco RAFI US 1500 Small-Mid ETF
SMB
Adj. R2
0.974
Rel. Sharpe
0.963
Mkt beta
1.02
AUM
US$2.7B
MER
0.34%
Valuation
153

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
ISMD
+0.83
|t|
+16.9
PRFZ
+0.80
|t|
+27.9
diff +0.02
HML
ISMD
+0.20
|t|
+4.6
PRFZ
+0.18
|t|
+6.3
diff +0.02
RMW
ISMD
-0.00
|t|
-0.1
PRFZ
+0.00
|t|
+0.0
diff -0.00
CMA
ISMD
+0.11
|t|
+1.8
PRFZ
+0.06
|t|
+1.3
diff +0.06
UMD
ISMD
+0.00
|t|
+0.0
PRFZ
-0.08
|t|
-5.0
diff +0.08

Why This Pair Matches

Exposure level
85
Exposure shape
100
Mkt beta diff
0.05
Rel. Sharpe diff
0.045

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

ISMD fund page PRFZ fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.